LOI Due Dates:
- Cycle 1: April 10, 2020
- Cycle 2: July 10, 2020
- Cycle 3: October 9, 2020
Drug Development Program
The goal of this RFP is to develop therapeutics for Alzheimer’s disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. Average Award: Up to $600,000 based on stage and scope of research.
Program to Accelerate Clinical Trials (PACT)
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. Average Award: Up to $3,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
Neuroimaging and CSF Biomarker Development Prgram
The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. Average award: Up to $600,000 based on stage and scope of research.
Prevention Beyond the Pipeline
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Average awards: $50,000-$100,000 for epidemiological analyses, and u to $3,000,000 for clinical trials based on stage and scope of research.